Source: DW News
Summary
India’s GLP-1 market has surged tenfold following the expiration of semaglutide’s patent, resulting in an 80% price drop. This boom in weight-loss drugs highlights a significant shift in pharmaceutical access and affordability in the region.
Why It Matters
The rise of affordable weight-loss medications in India is transformative, providing new options for millions struggling with obesity. As the market evolves, it could reshape healthcare priorities and ethical considerations in pharmaceutical pricing globally.






